Business
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease researchWESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors. Dr. Kester is a globally recognized infectiou
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"Turn Therapeutics","displaySize":"","headline":null,"caption":"Turn Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uTv2v5jICXhGET5aPRSD4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2e45caf24b7062b91032e0e4351b1e39","width":300,"height":101}},"lazy":false},{"type":"text","content":"Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research","length":142,"tagName":"p"},{"type":"text","content":"WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to its Board of Directors.","length":316,"tagName":"p"},{"type":"text","content":"Dr. Kester is a globally recognized infectious disease physician and R&D leader with extensive experience spanning clinical development, translational medicine, vaccine and anti-infective innovation, and public-private collaboration. A retired U.S. Army Colonel, he has held senior leadership roles across industry and academia, including as Commander of the Walter Reed Army Institute of Research, and has led multi-center clinical programs from Phase 1 through pivotal studies. He has also served on numerous advisory groups focused on global health security and emerging pathogens.","length":588,"tagName":"p"},{"type":"text","content":"Turn Therapeutics CEO Bradley Burnam commented, “Dr. Kester’s appointment adds world-class clinical and scientific leadership to our Board at a pivotal time as we prepare for the next phase of our growth. His depth of experience in drug development, infectious disease, and translational medicine will be invaluable as we advance our late-stage programs and approach key regulatory milestones. Dr. Kester’s perspective will strengthen our governance, sharpen our strategy, and help to ensure that our mission remains focused on patient impact and long-term value creation.”","length":573,"tagName":"p"},{"type":"text","content":"D...